Showing results (491-500 of 2,509) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|February 1, 2023
Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System LymphomaRui Zhang, Boyuan Wei, Yiyang Hu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 19, 2022
Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical TrialsAdemola S Ojo, Oluwasegun Akinyemi, Mojisola O Araoye, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 12, 2023
Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysisJoseph Ficek, Eleftheria Kalaitzaki, Shuai Sammy Yuan, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2022
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) RegistryJoanna Góra-Tybor, Aleksandra Gołos, Damian Mikulski, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 25, 2025
The Double-Faced t(12;21) in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Patients: Seven Years Experience at a Tertiary CenterEman O Rasekh, Mustafa Selim, Omar Arafah, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2025
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic ProfilingGiuseppe Bertuglia, Elisa Seneca, Timothy Corbett, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 21, 2025
Cardiovascular Safety of Carfilzomib in Patients with Multiple MyelomaAnastasios Tentolouris, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 12, 2025
SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell LymphomasAdam J Olszewski
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative AnalysisJavier Munoz, Allison Rosenthal, Andrew Ip, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2026
Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric AnalysisArne Strotmann, Theo Leitner, Paolo Mazzeo, et al.
Pageof 251